Evidence map›Paper›PMID 24670651›Full record

ArticleNature2014

Identification of genomic alterations in oesophageal squamous cell cancer.

Yongmei Song, Lin Li, Yunwei Ou, Zhibo Gao, Enmin Li, Xiangchun Li, Weimin Zhang, Jiaqian Wang, Liyan Xu, Yong Zhou and 36 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 660 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
660citing papers in PubMed, 4 pooled it
87.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

660 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,117 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Downregulation ofJournal of thoracic disease · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Esophageal cancer: from pathogenesis to precision therapies.Signal transduction and targeted therapy · 2026
    Review
  17. Review
  18. Article
  19. Article
  20. Article

600 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors at 6 institutions in 1 country.

Yongmei Song1] State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China [2].
Lin Li1] BGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China [2].
Yunwei Ou1] State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China [2] Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China [3].
Zhibo Gao1] BGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China [2].
Enmin Li1] Department of Biochemistry and Molecular Biology, The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, Guangdong, China [2].
Xiangchun Li1] BGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China [2].
Weimin ZhangState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Jiaqian WangBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Liyan XuInstitute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, Guangdong, China.
Yong ZhouBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Xiaojuan MaState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Lingyan LiuState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zitong ZhaoState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xuanlin HuangBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Jing FanState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Lijia DongState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Gang ChenBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Liying MaState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Jie YangBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Longyun ChenBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Minghui HeBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Miao LiBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Xuehan ZhuangBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Kai HuangBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Kunlong QiuBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Guangliang YinBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Guangwu GuoBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Qiang FengBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Peishan ChenBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Zhiyong WuDepartment of Tumor Surgery, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou 515041, Guangdong, China.
Jianyi WuDepartment of Biochemistry and Molecular Biology, The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, Guangdong, China.
Ling MaState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Jinyang ZhaoBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Longhai LuoBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Ming FuState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Bainan XuDepartment of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China.
Bo ChenInstitute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, Guangdong, China.
Yingrui LiBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Tong TongState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Mingrong WangState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhihua LiuState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Dongxin LinState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xiuqing ZhangBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Huanming YangBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Jun WangBGI-Shenzhen, Shenzhen 518083, Guangdong 518083, China.
Qimin ZhanState Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
BGI Group (China) · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNShantou University · CNShantou University Medical College · CNChinese PLA General Hospital · CNShantou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oesophageal cancer is one of the most aggressive cancers and is the sixth leading cause of cancer death worldwide. Approximately 70% of global oesophageal cancer cases occur in China, with oesophageal squamous cell carcinoma (ESCC) being the histopathological form in the vast majority of cases (>90%). Currently, there are limited clinical approaches for the early diagnosis and treatment of ESCC, resulting in a 10% five-year survival rate for patients. However, the full repertoire of genomic events leading to the pathogenesis of ESCC remains unclear. Here we describe a comprehensive genomic analysis of 158 ESCC cases, as part of the International Cancer Genome Consortium research project. We conducted whole-genome sequencing in 17 ESCC cases and whole-exome sequencing in 71 cases, of which 53 cases, plus an additional 70 ESCC cases not used in the whole-genome and whole-exome sequencing, were subjected to array comparative genomic hybridization analysis. We identified eight significantly mutated genes, of which six are well known tumour-associated genes (TP53, RB1, CDKN2A, PIK3CA, NOTCH1, NFE2L2), and two have not previously been described in ESCC (ADAM29 and FAM135B). Notably, FAM135B is identified as a novel cancer-implicated gene as assayed for its ability to promote malignancy of ESCC cells. Additionally, MIR548K, a microRNA encoded in the amplified 11q13.3-13.4 region, is characterized as a novel oncogene, and functional assays demonstrate that MIR548K enhances malignant phenotypes of ESCC cells. Moreover, we have found that several important histone regulator genes (MLL2 (also called KMT2D), ASH1L, MLL3 (KMT2C), SETD1B, CREBBP and EP300) are frequently altered in ESCC. Pathway assessment reveals that somatic aberrations are mainly involved in the Wnt, cell cycle and Notch pathways. Genomic analyses suggest that ESCC and head and neck squamous cell carcinoma share some common pathogenic mechanisms, and ESCC development is associated with alcohol drinking. This study has explored novel biological markers and tumorigenic pathways that would greatly improve therapeutic strategies for ESCC.

Indexed as

Alcohol DrinkingBiomarkers, TumorCarcinoma, Squamous CellCell CycleChromosomes, Human, Pair 11Comparative Genomic HybridizationDNA Copy Number VariationsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaExomeFemaleGenome, HumanGenomicsHistonesHumansMaleBiomarkers, TumorHistonesMicroRNAsMIRN548 microRNA, humanReceptors, Notch

Identifiers

PMID24670651
OpenAlexW2129138183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.